Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adimanebart PK and Bioavailability Study in Healthy Adults
NCT07673601Phase 1Recruiting
- Sponsor
- argenx
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adimanebart (6 arms), sponsored by argenx. Primary endpoint: Area Under the Curve from time zero to infinity up to 20 weeks. Started Jun 2026; status: recruiting.
02
Drugs
adimanebart
Beyond the preview
Go deeper on NCT07673601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673601.